EP4132569A4 - Anti-phf-tau antibodies and uses thereof - Google Patents
Anti-phf-tau antibodies and uses thereofInfo
- Publication number
- EP4132569A4 EP4132569A4 EP21783771.5A EP21783771A EP4132569A4 EP 4132569 A4 EP4132569 A4 EP 4132569A4 EP 21783771 A EP21783771 A EP 21783771A EP 4132569 A4 EP4132569 A4 EP 4132569A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- phf
- tau antibodies
- tau
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063007118P | 2020-04-08 | 2020-04-08 | |
US202063026387P | 2020-05-18 | 2020-05-18 | |
PCT/IB2021/052890 WO2021205359A1 (en) | 2020-04-08 | 2021-04-07 | Anti-phf-tau antibodies and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
EP4132569A1 EP4132569A1 (en) | 2023-02-15 |
EP4132569A4 true EP4132569A4 (en) | 2024-07-31 |
Family
ID=78023121
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21783771.5A Pending EP4132569A4 (en) | 2020-04-08 | 2021-04-07 | Anti-phf-tau antibodies and uses thereof |
Country Status (18)
Country | Link |
---|---|
US (1) | US20230151083A1 (en) |
EP (1) | EP4132569A4 (en) |
JP (1) | JP2023521763A (en) |
KR (1) | KR20220166308A (en) |
CN (1) | CN115697393A (en) |
AU (1) | AU2021251486A1 (en) |
BR (1) | BR112022020410A2 (en) |
CA (1) | CA3179914A1 (en) |
CL (1) | CL2022002766A1 (en) |
CO (1) | CO2022015737A2 (en) |
CR (1) | CR20220505A (en) |
DO (1) | DOP2022000218A (en) |
EC (1) | ECSP22078815A (en) |
IL (1) | IL297231A (en) |
MX (1) | MX2022012628A (en) |
PE (1) | PE20230385A1 (en) |
TW (1) | TW202204402A (en) |
WO (1) | WO2021205359A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023092004A1 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
TW202345899A (en) * | 2022-03-11 | 2023-12-01 | 比利時商健生藥品公司 | Multispecific antibodies and uses thereof |
WO2023170290A1 (en) * | 2022-03-11 | 2023-09-14 | Janssen Pharmaceutica Nv | Multispecific antibodies and uses thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013096380A2 (en) * | 2011-12-20 | 2013-06-27 | Janssen Biotech, Inc. | Anti-phf-tau antibodies and their uses |
WO2016112078A2 (en) * | 2015-01-08 | 2016-07-14 | Janssen Biotech, Inc. | Anti-phf-tau antibodies and their uses |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TN2017000543A1 (en) * | 2015-07-06 | 2019-04-12 | Ucb Biopharma Sprl | Tau-binding antibodies |
CN106939047B (en) * | 2016-01-04 | 2021-08-31 | 江苏怀瑜药业有限公司 | PD-L1 antibody and preparation method thereof |
JOP20180021A1 (en) * | 2017-03-16 | 2019-01-30 | Janssen Biotech Inc | Anti-phf-tau antibodies and uses thereof |
-
2021
- 2021-04-07 CA CA3179914A patent/CA3179914A1/en active Pending
- 2021-04-07 JP JP2022561415A patent/JP2023521763A/en active Pending
- 2021-04-07 AU AU2021251486A patent/AU2021251486A1/en active Pending
- 2021-04-07 CR CR20220505A patent/CR20220505A/en unknown
- 2021-04-07 IL IL297231A patent/IL297231A/en unknown
- 2021-04-07 EP EP21783771.5A patent/EP4132569A4/en active Pending
- 2021-04-07 WO PCT/IB2021/052890 patent/WO2021205359A1/en active Application Filing
- 2021-04-07 CN CN202180041278.1A patent/CN115697393A/en active Pending
- 2021-04-07 PE PE2022002218A patent/PE20230385A1/en unknown
- 2021-04-07 KR KR1020227038806A patent/KR20220166308A/en active Search and Examination
- 2021-04-07 MX MX2022012628A patent/MX2022012628A/en unknown
- 2021-04-07 US US17/917,916 patent/US20230151083A1/en active Pending
- 2021-04-07 BR BR112022020410A patent/BR112022020410A2/en unknown
- 2021-04-08 TW TW110112656A patent/TW202204402A/en unknown
-
2022
- 2022-10-06 CL CL2022002766A patent/CL2022002766A1/en unknown
- 2022-10-07 DO DO2022000218A patent/DOP2022000218A/en unknown
- 2022-10-07 EC ECSENADI202278815A patent/ECSP22078815A/en unknown
- 2022-10-31 CO CONC2022/0015737A patent/CO2022015737A2/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013096380A2 (en) * | 2011-12-20 | 2013-06-27 | Janssen Biotech, Inc. | Anti-phf-tau antibodies and their uses |
WO2016112078A2 (en) * | 2015-01-08 | 2016-07-14 | Janssen Biotech, Inc. | Anti-phf-tau antibodies and their uses |
Non-Patent Citations (2)
Title |
---|
See also references of WO2021205359A1 * |
VANDERMEEREN MARC ET AL: "Anti-Tau Monoclonal Antibodies Derived from Soluble and Filamentous Tau Show Diverse Functional Properties in vitro and in vivo", JOURNAL OF ALZHEIMER`S DISEASE, vol. 65, no. 1, 7 August 2018 (2018-08-07), NL, pages 265 - 281, XP055860147, ISSN: 1387-2877, Retrieved from the Internet <URL:http://dx.doi.org/10.3233/JAD-180404> DOI: 10.3233/JAD-180404 * |
Also Published As
Publication number | Publication date |
---|---|
MX2022012628A (en) | 2023-01-11 |
EP4132569A1 (en) | 2023-02-15 |
IL297231A (en) | 2022-12-01 |
CL2022002766A1 (en) | 2023-04-21 |
AU2021251486A1 (en) | 2022-12-08 |
DOP2022000218A (en) | 2023-04-30 |
TW202204402A (en) | 2022-02-01 |
CN115697393A (en) | 2023-02-03 |
CR20220505A (en) | 2023-05-31 |
CA3179914A1 (en) | 2021-10-14 |
BR112022020410A2 (en) | 2023-01-03 |
PE20230385A1 (en) | 2023-03-06 |
ECSP22078815A (en) | 2022-11-30 |
KR20220166308A (en) | 2022-12-16 |
JP2023521763A (en) | 2023-05-25 |
CO2022015737A2 (en) | 2023-02-27 |
US20230151083A1 (en) | 2023-05-18 |
WO2021205359A1 (en) | 2021-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP4141029A4 (en) | Antibody against nectin-4 and application thereof | |
GB202017058D0 (en) | Antibodies and uses thereof | |
IL289585A (en) | Dll3-targeting antibodies and uses thereof | |
IL275826A (en) | Anti-mct1 antibodies and uses thereof | |
EP4146272A4 (en) | Covid-19 antibodies and uses thereof | |
SG11202112112UA (en) | Anti-galectin-9 antibodies and uses thereof | |
EP4169948A4 (en) | Anti-cd73 antibody and use thereof | |
EP4141030A4 (en) | Anti-cd73 antibody and use thereof | |
IL308808A (en) | Anti-ccr8 antibodies and uses thereof | |
EP4132569A4 (en) | Anti-phf-tau antibodies and uses thereof | |
IL291027A (en) | Anti-steap1 antibodies and uses thereof | |
IL289656A (en) | Anti-tigit antibodies and application thereof | |
IL287690A (en) | Anti-hvem antibodies and use thereof | |
IL307267A (en) | Anti-cd122 antibodies and uses thereof | |
IL308382A (en) | Novel anti-cd276 antibodies and the uses thereof | |
IL291550A (en) | Anti-il-27 antibodies and uses thereof | |
IL291546A (en) | Anti-kir3dl3 antibodies and uses thereof | |
IL291280A (en) | Anti-cd371 antibodies and uses thereof | |
EP4163300A4 (en) | Gfral-antagonistic antibody and use thereof | |
IL304412A (en) | Antibodies against cd112r and uses thereof | |
IL308198A (en) | Anti-il-27 antibodies and uses thereof | |
IL307940A (en) | Anti-adgre2 antibodies and uses thereof | |
EP4339208A4 (en) | Anti-tigit antibodies and use thereof | |
IL288807A (en) | Anti-talen antibodies and uses thereof | |
EP4299590A4 (en) | Anti-siglec15 antibody and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20221108 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 9/00 20060101ALI20240402BHEP Ipc: A61K 39/395 20060101ALI20240402BHEP Ipc: A61K 39/00 20060101AFI20240402BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20240701 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 9/00 20060101ALI20240625BHEP Ipc: A61K 39/395 20060101ALI20240625BHEP Ipc: A61K 39/00 20060101AFI20240625BHEP |